Advertisement

Supportive Care in Cancer

, Volume 25, Issue 1, pp 229–236 | Cite as

Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients

  • Ali AlkanEmail author
  • Arzu Yaşar
  • Ebru Karcı
  • Elif Berna Köksoy
  • Muslih Ürün
  • Filiz Çay Şenler
  • Yüksel Ürün
  • Gülseren Tuncay
  • Hakan Ergün
  • Hakan Akbulut
Original Article

Abstract

Purpose

Due to more comorbidities, polypharmacy is common in elderly patients and drug interactions are inevitable. It is also challenging to treat an elderly patient with a diagnosis of cancer. Prevalence and clinical impacts of drug interactions and using potentially inappropriate medications (PIMs) have been studied in geriatric patients. However, these are not well defined in oncology practice. The purpose of this study is to define the prevalence of PIMs and severe drug interactions (SDIs) in elderly cancer patients and investigate the factors associated with them.

Methods

Patients more than 65 years of age in both inpatient and outpatient clinics were evaluated. Patient, disease characteristics, and medications used were collected by self reports and medical records. Drug interactions were checked with Lexicomp® and PIM was defined with 2012 update of Beers criteria. Severe drug interactions are defined with category D or X DIs. Logistic regression was used to compute odds ratios (ORs) and 95 % confidence intervals (CIs) for the association between SDIs, PIMs, and clinical parameters.

Results

Four hundered and forty-five elderly patients (286 outpatient, 159 inpatient), with a median age of 70 (65–89) were evaluated. SDIs were present in 156 (35.1 %) of patients, 81 (28.3 %), and 75 (47.2 %) for outpatient and inpatients, respectively (p < 0.001). PIMs were present in 117 (26.6 %) of the patients, 40 (14.2 %), and 77(48.4 %) for outpatient and inpatients, respectively (p < 0.001). In multivariate analysis; polypharmacy (≥5 drugs), inpatient status and diagnosis of lung cancer were associated with severe DIs. Polypharmacy, inpatient status, and bad performance score (ECOG 3–4) were associated with PIMs.

Conclusions

Nearly one third of the elderly cancer patients are exposed to severe drug interactions and PIMs. Clinicians dealing with elderly cancer patients should be more cautious when prescribing/ planning drugs to this group of patients. More strategies should be developed in this group of patients to minimize the medications prescribed and prevent severe DIs.

Keywords

Severe drug interaction Potentially inappropriate medication Elderly Beers Criteria Geriatric oncology Polypharmacy 

Notes

Compliance with ethical standards

Conflict of interest

There is no conflict of interest. The study has not been supported or funded by any organization, group, or society. The report has been written with contributions of all authors, and all of the authors are in agreement with the content of the manuscript.

Supplementary material

520_2016_3409_MOESM1_ESM.docx (13 kb)
ESM 1 (DOCX 13 kb)

References

  1. 1.
    Marcum ZA, Amuan ME, Hanlon JT, Aspinall SL, Handler SM, Ruby CM, et al. (2012) Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans. J Am Geriatr Soc 60(1):34–41CrossRefPubMedGoogle Scholar
  2. 2.
    Tam-McDevitt J (2008) Polypharmacy, aging, and cancer. Oncology (Williston Park) 22(9):1052–1055 discussion 5, 8, 60Google Scholar
  3. 3.
    Turner JP, Jamsen KM, Shakib S, Singhal N, Prowse R, Bell JS (2016) Polypharmacy cut-points in older people with cancer: how many medications are too many? Support Care Cancer 24(4):1831–1840CrossRefPubMedGoogle Scholar
  4. 4.
    Popa MA, Wallace KJ, Brunello A, Extermann M, Balducci L (2014) Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy. J Geriatr Oncol 5(3):307–314CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    American Geriatrics Society Beers Criteria Update Expert P (2012) American Geriatrics Society updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 60(4):616–631CrossRefGoogle Scholar
  6. 6.
    Guaraldo L, Cano FG, Damasceno GS, Rozenfeld S (2011) Inappropriate medication use among the elderly: a systematic review of administrative databases. BMC Geriatr 11:79CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Jyrkka J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S (2009) Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging 26(12):1039–1048CrossRefPubMedGoogle Scholar
  8. 8.
    Saarelainen LK, Turner JP, Shakib S, Singhal N, Hogan-Doran J, Prowse R, et al. (2014) Potentially inappropriate medication use in older people with cancer: prevalence and correlates. J Geriatr Oncol. 5(4):439–446CrossRefPubMedGoogle Scholar
  9. 9.
    Park JW, Roh JL, Lee SW, Kim SB, Choi SH, Nam SY, et al. (2016) Effect of polypharmacy and potentially inappropriate medications on treatment and posttreatment courses in elderly patients with head and neck cancer. J Cancer Res Clin Oncol 142(5):1031–1040CrossRefPubMedGoogle Scholar
  10. 10.
    Maggiore RJ, Dale W, Gross CP, Feng T, Tew WP, Mohile SG, et al. (2014) Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment. J Am Geriatr Soc 62(8):1505–1512CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Drugs & Drug Interaction (2016, January 7) Retrieved from http://www.uptodate.com/home/drugs-drug-interaction
  12. 12.
    Lichtman SM, Boparai MK (2008) Anticancer drug therapy in the older cancer patient: pharmacology and polypharmacy. Curr Treat Options in Oncol 9(2–3):191–203CrossRefGoogle Scholar
  13. 13.
    Misra D, Seo PH, Cohen HJ (2004) Aging and cancer. Clinical advances in hematology & oncology: H&O 2(7):457–465Google Scholar
  14. 14.
    Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA (2003) Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 289(13):1652–1658CrossRefPubMedGoogle Scholar
  15. 15.
    Riechelmann RP, Zimmermann C, Chin SN, Wang L, O’Carroll A, Zarinehbaf S, et al. (2008) Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manag 35(5):535–543CrossRefGoogle Scholar
  16. 16.
    Kierner KA, Weixler D, Masel EK, Gartner V, Watzke HH (2016) Polypharmacy in the terminal stage of cancer. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 24(5):2067–2074CrossRefGoogle Scholar
  17. 17.
    Riechelmann RP, Moreira F, Smaletz O, Saad ED (2005) Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 56(3):286–290CrossRefPubMedGoogle Scholar
  18. 18.
    van Leeuwen RW, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG (2011) Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol 22(10):2334–2341CrossRefPubMedGoogle Scholar
  19. 19.
    Dushenkov A, Kalabalik J, Carbone A, Jungsuwadee P (2016) Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice. J Oncol Pharm Pract. doi: 10.1177/1078155216631408
  20. 20.
    Ryan C, O’Mahony D, Kennedy J, Weedle P, Barry P, Gallagher P, et al. (2009) Appropriate prescribing in the elderly: an investigation of two screening tools, beers criteria considering diagnosis and independent of diagnosis and improved prescribing in the elderly tool to identify inappropriate use of medicines in the elderly in primary care in Ireland. J Clin Pharm Ther 34(4):369–376CrossRefPubMedGoogle Scholar
  21. 21.
    Prithviraj GK, Koroukian S, Margevicius S, Berger NA, Bagai R, Owusu C (2012) Patient characteristics associated with polypharmacy and inappropriate prescribing of medications among older adults with cancer. Journal of geriatric oncology 3(3):228–237CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Nightingale G, Hajjar E, Swartz K, Andrel-Sendecki J, Chapman A (2015) Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol 33(13):1453–1459CrossRefPubMedGoogle Scholar
  23. 23.
    Maggiore RJ, Gross CP, Hurria A (2010) Polypharmacy in older adults with cancer. Oncologist 15(5):507–522CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Ali Alkan
    • 1
    Email author
  • Arzu Yaşar
    • 1
  • Ebru Karcı
    • 1
  • Elif Berna Köksoy
    • 1
  • Muslih Ürün
    • 1
  • Filiz Çay Şenler
    • 1
  • Yüksel Ürün
    • 1
  • Gülseren Tuncay
    • 2
  • Hakan Ergün
    • 3
  • Hakan Akbulut
    • 1
  1. 1.Medical OncologyAnkara University School of MedicineAnkaraTurkey
  2. 2.Internal MedicineAnkara University School of MedicineAnkaraTurkey
  3. 3.PharmacologyAnkara University School of MedicineAnkaraTurkey

Personalised recommendations